Publication date: May 2017
Source:Neuroimaging Clinics of North America, Volume 27, Issue 2
Author(s): Angela Vidal-Jordana, Xavier Montalban
Teaser
Multiple sclerosis (MS) is a chronic autoimmune and degenerative disease of the central nervous system that affects young people. MS develops in genetically susceptible individuals exposed to different unknown triggering factors. Different phenotypes are described. About 15% of patients present with a primary progressive course and 85% with a relapsing-remitting course. An increasing number of disease-modifying treatments has emerged. Although encouraging, the number of drugs challenges the neurologist because each treatment has its own risk–benefit profile. Patients should be involved in the decision-making process to ensure good treatment and safety monitoring adherence.http://ift.tt/2nsw4RH
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου